UNSPSC 51182056: Nandrolone cyclohexylpropionate

This classification denotes a therapeutic androgen and anabolic steroid C27H40O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4NE48GG1Y, chemically known as estr-4-en-3-one, 17-(3-cyclohexyl-1-oxopropoxy)-, (17.beta.)-, but more generally known as nandrolone cyclohexylpropionate, which bears US NIH Compound Identifier 101905. European Medicines Agency schedules Nandrolone cyclohexylpropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23549.

UNSPSC 51182056 Nandrolone cyclohexylpropionate, a Commodity code, covers anabolic steroids and related pharmaceutical compounds procured by state and local health agencies, correctional facilities, and other government entities for medical use. State and local governments buy nandrolone and similar controlled pharmaceutical products through cooperative purchasing agreements and direct solicitations, typically specifying National Drug Codes (NDC), required dosage forms, and FDA compliance. The code encompasses the full lifecycle from vendor certification through authorized wholesaler distribution channels, with buyers enforcing manufacturing-practice standards and supply-chain security requirements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon. The MMCAP solicitation (S1070000015802) requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates certification of current Good Manufacturing Practices (cGMP) compliance, Drug Supply Chain Security Act (DSCSA) compliance, contractual relationships with at least two of the three wholesalers, and commercial general liability insurance of $5,000,000 per occurrence. Evaluation weighs price competitiveness at 75 percent, with secondary criteria including fixed pricing structure (10 percent), administrative compliance (5 percent), EDI capability (5 percent), and acceptance of a 3 percent administrative fee (5 percent). The contract term spans two years for new vendors, effective July 1, 2026, with optional extensions at MMCAP's discretion, and MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and patient safety.